Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740806 | 0.84 | POLB (0.39) | BDKRB2OPRM1SIGMAR1KCNH2POLB | |
| SCHEMBL3979671 | 0.81 | OPRM1 (0.40) | OPRM1SIGMAR1POLBOPRD1ALDH1A1 | |
| SCHEMBL739715 | 0.81 | SIGMAR1 (0.44) | BDKRB2OPRM1SIGMAR1KCNH2HTT | |
| SCHEMBL4772742 | 0.74 | SIGMAR1 (0.41) | BDKRB2OPRM1SIGMAR1POLBOPRD1 | |
| SCHEMBL4772739 | 0.74 | SIGMAR1 (0.41) | BDKRB2OPRM1SIGMAR1POLBOPRD1 | |
| SCHEMBL2761877 | 0.72 | ACHE (0.44) | OPRM1SIGMAR1KCNH2POLBHTT | |
| SCHEMBL740951 | 0.69 | KMT2A (0.44) | OPRM1OPRD1KMT2A | |
| SCHEMBL3566447 | 0.67 | SLC6A3 (0.54) | OPRM1SIGMAR1KCNH2OPRD1ACHE | |
| SCHEMBL2762344 | 0.67 | SIGMAR1 (0.43) | OPRM1SIGMAR1KCNH2GRM2ALDH1A1 | |
| SCHEMBL2762030 | 0.66 | SIGMAR1 (0.42) | OPRM1SIGMAR1KCNH2POLBGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842818-B2 | Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | claimed |
| US-20090270637-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-10-29 | — | — | US | claimed |
| EP-1930321-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | claimed |
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8378119-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-2000467-A9 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2000467-A2 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| EP-1930321-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1882685-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DHPS, COASY, NQO2 | BDKRB2 4704/4885OPRM1 3694/4885SIGMAR1 3402/4885 |
| US-20090270637-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | DHPS, SQLE, NQO2 | BDKRB2 4090/4885OPRM1 3784/4885SIGMAR1 3153/4885 |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | BDKRB2 3721/4885OPRM1 606/4885SIGMAR1 113/4885 |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, ARL1, NQO2 | BDKRB2 4382/4885OPRM1 2105/4885SIGMAR1 1394/4885 |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | BDKRB2 4242/4885OPRM1 765/4885SIGMAR1 872/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | BDKRB2 4165/4885OPRM1 821/4885SIGMAR1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.